NMN vs NAD+ vs Resveratrol — What Actually Extends Life?

NMN, NAD+, and resveratrol regularly show up next to each other on the same supplement store shelf, in the same "hacking aging" article, and often in the same stack on a longevity enthusiast's desk. That's understandable — all three circle the same hypothesis: that raising cellular NAD+ levels, directly or indirectly, might slow down certain aspects of aging. The problem is that this is one shared hypothesis wrapped around three very different products, with very different amounts and quality of evidence behind each one.

This piece doesn't repeat what we've already covered separately in our knowledge base on NMN and on resveratrol — you'll find the full mechanism, dosing, contraindications, and history of each compound there. This is about something different: putting all three side by side and giving an honest answer to the question of which one, if any, has enough evidence in humans today to justify spending money on it — and which are still speculative bets on the future of science.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell in the body, essential for mitochondrial energy production, DNA repair, and the activity of sirtuins — a group of enzymes linked in animal models to the longevity mechanisms activated by caloric restriction. Its level naturally declines with age, dropping by as much as half in people 60+ compared with young adults. That decline is the starting point for all three strategies covered in this article — they differ only in where along this metabolic pathway they try to intervene.

NMN (nicotinamide mononucleotide) is a direct precursor of NAD+ — the body converts it into NAD+ through a two-step metabolic pathway. Direct NAD+ supplementation tries to skip that step and deliver the finished coenzyme itself, orally or intravenously. Resveratrol works completely differently — it doesn't raise NAD+ levels, it tries to activate sirtuins (SIRT1 above all), the enzymes that need NAD+ as fuel to function in the first place. That theoretically means resveratrol and NAD+ precursors could complement each other — but that's still a hypothesis with weak clinical confirmation in humans, not an established fact.

Of the three compounds discussed here, NMN has seen the largest number of randomized human trials in recent years — which doesn't mean a large number in absolute terms. In a randomized trial by Yoshino et al. from 2021, ten weeks of NMN supplementation improved muscle insulin sensitivity in women with prediabetes, though it had no significant effect on body weight or other metabolic markers — and the trial included only 25 participants.

Later studies broadened this picture without changing its fundamental character. In a study published in 2022, Igarashi et al. gave healthy older men 250 mg of NMN daily for 12 weeks — supplementation raised blood NAD+ levels and partially improved muscle function (walking speed, grip strength), with good tolerability. A separate 2022 study by Kim et al., also in older adults in Japan, described improved sleep quality and reduced fatigue after 12 weeks of NMN — and a larger, multicenter dose-response study by Yi et al. from 2023 confirmed a good safety profile for NMN in healthy middle-aged adults across a range of doses.

It's worth pausing on what these studies actually measured: blood NAD+ level, insulin sensitivity, grip strength, sleep quality. Those are real, objectively measurable parameters — but none of them is the same thing as lifespan or mortality. The studies ran for a few to a dozen or so weeks, enrolled anywhere from a few dozen to just under two hundred participants, and mostly came from a single region (Japan). That's a solid but still early foundation — not a confirmed anti-aging intervention.

If the problem is a declining NAD+ level, why not just deliver it directly? In theory, this is the most intuitive approach of the three — in practice, it's a surprisingly under-confirmed area, despite aggressive marketing, especially around intravenous NAD+ infusions offered at private wellness clinics. NAD+ itself is a large, charged molecule with questionable stability and oral absorption, which is one of the reasons researchers have focused more on smaller precursors, such as NMN or NR (nicotinamide riboside), than on the molecule itself.

As a result, while NAD+ precursors already have a handful of randomized trials with specific endpoints behind them, solid, peer-reviewed clinical trials evaluating the safety and efficacy of direct NAD+ supplementation itself — oral or intravenous — are noticeably fewer than for NMN. Available data on intravenous infusions mostly comes from small, early pilot studies, often not yet published as full, peer-reviewed papers — which is itself a signal that this area is at an earlier stage than NMN supplementation.

That doesn't mean direct NAD+ is worthless by definition — it's an area too young to render that verdict either way. What it does mean is that, of the three options discussed here, this one currently has the thinnest evidence file in humans relative to the price you pay for it.

Resveratrol's story is completely different from NMN's. This polyphenol from red grape skins gained fame back in the mid-2000s, partly as a scientific explanation for the so-called "French paradox," and the media breakthrough was a widely covered 2006 study by Baur et al., linked to David Sinclair's lab at Harvard — it showed that resveratrol improved health parameters and extended survival in mice fed a high-calorie diet.

This result, though real and published in Nature, concerned a specific model — mice on a high-calorie diet, not healthy, young animals on a standard diet. Subsequent years also brought something rarely mentioned in popular articles about resveratrol: a serious scientific doubt about the mechanism itself. In 2010, Pacholec et al.'s team showed that resveratrol and related compounds activated SIRT1 only when the lab assay used a substrate with an artificially attached fluorophore — with natural, unmodified protein substrates, this activation effect largely disappeared. In other words, some of the early, spectacular results may have been a methodological artifact of the assay, not evidence of a real mechanism of action in the cell.

On top of that comes a purely pharmacokinetic problem, independent of the mechanism debate: orally administered resveratrol is very rapidly metabolized by the liver and intestines before it can reach target tissues at a meaningful concentration. Walle's classic 2011 paper describes absorption of around 75%, but systemic bioavailability well below 1% due to this rapid first-pass metabolism. That's one of the main reasons the impressive results from cell-culture studies — which use much higher concentrations than are achievable in the body — translate so poorly into what actually happens in a human after a standard oral dose.

Despite these limitations, resveratrol today has more, and a longer history of, human research with concrete, if modest, results than direct NAD+ supplementation. A 2019 meta-analysis by Fogacci et al., covering randomized trials, found that resveratrol at doses above 300 mg/day significantly lowered blood pressure, while lower doses showed no such effect — one of the few examples among these three compounds where the effect is clearly dose-dependent and reproducible across several studies at once.

All three compounds have impressive results in animal models — mice, yeast, nematodes — and it's precisely those results, not human clinical trials, that most often end up in popular science articles and supplement manufacturers' marketing materials. The problem is that animal models have much shorter lifespans, different metabolism, and different pharmacokinetics than humans, and the doses used in rodent studies, once converted to body weight, are often many times higher than anything anyone realistically takes in a supplement.

That's why, when evaluating each of these three compounds, it's worth asking yourself one honest question: does the evidence I'm citing come from a human study, or from an animal model? That distinction alone eliminates most of the overstated claims circulating around this topic.

Weighing price against the quality of evidence makes the picture more complicated than a simple "more expensive means better." NMN, costing roughly 250–500 PLN a month at typical dosing, currently has the most human research with concrete endpoints of the three — but those are still intermediate endpoints, not hard health outcomes. Resveratrol, usually costing 50–100 PLN a month (micronized or liposomal forms can run 30–50% more), has more years of research behind it and a reproducible, if modest, effect on blood pressure at a sufficiently high dose — at the lowest cost of the three. Direct NAD+, especially as IV infusions, is usually the most expensive option, while also having the thinnest evidence file in humans.

None of these three compounds has strong enough human evidence at this stage to be called a confirmed anti-aging intervention — that needs to be said plainly, regardless of how popular and expensive some of them have become. The differences between them are real, though, and worth knowing before you decide to buy.

NMN currently has the thickest file of clinical research of the three — several independent, randomized human trials with concrete, objectively measured results. That's a real argument for treating it as the most promising, if still early, hypothesis of the three, for people who knowingly accept the high cost and lack of a guarantee. Resveratrol is the cheapest and best-understood option in terms of risk — with a real, if modest, effect on blood pressure at the right dose, offset by very poor bioavailability that limits how large an effect oral supplementation can even achieve. Direct NAD+, especially as costly IV infusions, currently has the thinnest evidence file relative to price — an area where marketing has clearly outpaced the science more than with the other two.